Figure 2From: Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients(A) Updated Overall survival (OS) and (B) Event-free survival (EFS) for the whole group.Back to article page